DRUG
Semaglutide
Participants receive an 8-week subcutaneous semaglutide dose-escalation treatment using Wegovy: 0.25 mg once weekly for the first 4 weeks, followed by 0.5 mg once weekly for the next 4 weeks.
Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies
Status
Recruiting
Phase
Not applicable
Enrollment
30
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The goal of this clinical trial is to investigate how semaglutide affects the way the brain responds to food in adults with obesity and food addiction tendencies. The main goals of this study are: * To see if semaglutide changes dopamine-related activity in the brain during the look, smell, and drink period. * To see if semaglutide changes dopamine-related brain signals during the post-ingestive period. * To see if semaglutide changes psychological survey results and cognitive task results. Adults with obesity and food addiction tendencies will join this study. Each participant will receive semaglutide treatment for 8 weeks. Each participant will have two brain scans using \[11C\]raclopride PET. During each PET scan, participants will: * View food images. * Receive chocolate milk through a tube while lying in the scanner. * Use a tablet during the scan to rate their hunger, desire for the chocolate milk drink, and liking of the drink.
Full detailed description
1. Background and Rationale GLP-1 receptor agonists, including semaglutide, are effective treatments for obesity. However, the brain mechanisms underlying their effects on appetite, food reward, and eating behavior remain incompletely understood. Food-related visual and olfactory cues may engage dopamine-mediated reward pathways during the pre-ingestive phase, and post-ingestive signals may further influence dopamine signaling after food intake. This study will use \[11C\]raclopride positron emission tomography (PET) to assess dopamine-related binding measures in the human brain. The study will examine whether semaglutide changes dopamine-related brain responses during food cue and drink exposure and during the post-ingestive period. 2. Study Protocol and Procedures This is a prospective clinical trial using a 2-by-2 crossover design. Participants will receive once-weekly semaglutide treatment for 8 weeks and will undergo two \[11C\]raclopride PET scans. The scans will be performed under conditions with and without the effect of semaglutide, depending on group assignment. Before each PET imaging session, participants will complete baseline assessments, including body measurements, psychological surveys, and computer-based cognitive tasks. \[11C\]raclopride will then be administered according to the PET protocol. Participants will undergo brain PET imaging while lying in the scanner. During the imaging session, participants will complete a standardized chocolate milk drink task. This task includes a baseline period, exposure to chocolate milk images, smelling the chocolate milk drink, and the post-ingestive stage using the chocolate milk drink delivered through a tube. During the scan, participants will use a tablet to rate hunger, desire for the chocolate milk drink, and liking of the drink at set time points. The same PET task procedures will be used across study conditions. This will allow researchers to compare dopamine-related PET measures, psychological survey results, and cognitive task results between conditions with and without the effect of semaglutide.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jul 28, 2026
Study start
Jul 15, 2026
Primary completion
Feb 29, 2028
Study completion
Jun 30, 2028
Results posted
Not reported
Registry updated
Jul 28, 2026
Outcomes
What the study measures.
Primary outcomes
Change in Dopamine Binding Potential During the Look, Smell, and Drink Period
Time frame · Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
Dopamine D2/D3 receptor binding potential is measured using \[11C\]raclopride PET during the food cue and drink period. The outcome is the within-participant difference in binding potential between the on-drug and off-drug/post-washout conditions.
Secondary outcomes
Change in Dopamine Binding Potential During the Post-Ingestive Period
Time frame · Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
Dopamine D2/D3 receptor binding potential is measured using \[11C\]raclopride PET during the post-ingestive period after the drink. The outcome is the within-participant difference in binding potential between the on-drug and off-drug/post-washout conditions.
State Food Craving Score
Time frame · Immediately before and after PET imaging. Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
State food craving is assessed using the General Food Cravings Questionnaire-State (G-FCQ-S). Each of the 15 items is evaluated on a 0 to 100 scale, where higher scores indicate greater intensity of the felt state.
Chocolate Milk Liking, Chocolate Milk Wanting, and Fullness Ratings (VAS-100)
Time frame · During each 92-minute PET scan, at 10, 20, 30, 40, 50, 51, 54, 57, 60, 65, 70, 75, 80, 85, and 90 minutes.
Liking and wanting for the chocolate milk stimulus, as well as general fullness, are assessed repeatedly during PET imaging using 0-to-100 visual analogue scale ratings. For liking and wanting, higher scores indicate greater liking of or desire for the chocolate milk stimulus. For fullness, higher scores indicate greater subjective fullness. Ratings are collected at 15 predefined time points during each PET scan.
Food-Specific Attentional Bias
Time frame · Before PET imaging. Group A: At Baseline (Day 0) and 8 weeks (±3 days) after starting semaglutide. Group B: At 8 weeks (±3 days) after starting semaglutide and 8 weeks after semaglutide discontinuation.
Food-specific attentional bias is assessed using a computer-based dot-probe task with webcam-based eye tracking. Bias is calculated from reaction time differences between probes replacing food versus neutral images, and from gaze-based measures including dwell time toward food versus neutral images and first saccade direction. Higher values indicate greater attentional bias toward food stimuli.
Eligibility
Who can take part.
- Minimum age
- 19 Years
- Maximum age
- 50 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Participants aged between 19 and 50 years. * Eligible for treatment with semaglutide, defined as either: * Initial body mass index (BMI) of 30 kg/m2 or higher; or * Initial BMI of 27 kg/m2 to less than 30 kg/m2 with at least one weight-related comorbidity, such as dysglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. * Mild or greater food addiction tendency, defined as a Yale Food Addiction Scale (YFAS) score of 3 or higher. * Able to understand the study tasks and provide appropriate responses. Exclusion Criteria: * Use of medications that may affect body weight or dopaminergic medications within the past 2 months. * Known hypersensitivity to semaglutide. * Pregnant, breastfeeding, or planning to become pregnant. * Severe renal impairment, hepatic impairment, heart failure, acute pancreatitis, or thyroid disease. * Any medical condition, disease, or medical history that, in the investigator's judgment, would make it difficult for the participant to complete the study or would interfere with interpretation of the study results. * Allergy to ingredients in chocolate milk, including milk or soy, or to ingredients that may be present through cross-contamination, including egg, buckwheat, peanut, wheat, peach, tomato, walnut, pork, or beef. * Participants with both no self-reported preference for chocolate milk and a chocolate milk preference score of less than 5 on a 10-point visual analog scale (VAS).
Study locations
1 registered sites.
South Korea. Showing up to 24 locations stored in the fast local snapshot.
Seoul National University Hospital
Seoul, South Korea
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Semaglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Oelisoa Andriankaja · Obesity · Dental Care for Children
Not applicable
Not yet recruiting
50
2026-07
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc. · Overweight and/or Obesity
Phase 1
Recruiting
62
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Completed
884
2026-07
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
Imperial College London · Pulmonary Arterial Hypertension
Phase 2
Not yet recruiting
32
2026-07
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.